View More View Less
  • 1 Department of Zoology, Government College University Faisalabad, Faisalabad, Pakistan
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Abstract

World has been suffering from pandemic caused by mysterious Coronavirus. The novel member of Coronaviridae causing COVID-19 disease is named as SARS-Cov-2. Its first case was reported in China by the end of 2019, but its exponential spread has wrapped entire globe, suspended and is penalizing mankind. A retrospective meta-analysis study showed that outbreaks of Middle East Respiratory Syndrome (MERS) and SARS-Cov-1 (Coronaviridae), influenza infection H1N1 and West-African Ebola caused lower mortality than this new pandemic COVID-19. Virus has appeared as a new human pathogen so to counter COVID-19 no specific vaccine, monoclonal antibodies have been manufactured till day. The outbreak of novel Coronavirus is treated with antimicrobial drugs but they have their own mild side effects. But the drastic spread of COVID-19 compels us also to use other ways to counter pandemic. Thus, passive immunization can be opted to hold back this mysterious virus. Passive immunization has been in use since early 20th century and showed its effectiveness against all previous infectious outbreaks including MERS and SARS-Cov-1 members of Coronaviridae. The review argues that convalescent plasma is an explicit option for containment of COVID-19 disease.

  • [1]

    Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, A novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 382: 72733.

  • [2]

    Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 195366.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [3]

    Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Eng J Med 2012; 367: 181420.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [4]

    Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clinic Infect Dis 2015; 61: 496502.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [5]

    Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, SARS—beginning to understand a new virus. Nat Rev Microbiol 2003; 1(3): 209-18.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [6]

    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 26971.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [7]

    Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020; 130: 15458.

  • [8]

    Hopkins JS. Drugmaker Takeda Is Working on Coronavirus Drug. Wall Street J.2020.

  • [9]

    Perlman S, Vijay R. Middle East respiratory syndrome vaccines. Int J Infect Dis 2016; 47: 238.

  • [10]

    Liu Y, Li J, Feng Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Crit Care 2020; 24: 56.

  • [11]

    Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, Convalescent plasma: new evidence for an old therapeutic tool?. Blood Trans 2016; 14: 152.

    • Search Google Scholar
    • Export Citation
  • [12]

    Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211: 8090.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [13]

    Graham BS, Ambrosino DM. History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opinion HIV AIDS 2015; 10: 129.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [14]

    Shen, C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323: 158289.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [15]

    Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020.

  • [16]

    Park WH. Therapeutic use of antipoliomyelitis serum in preparalytic cases of poliomyelitis. J Amer Med Assoc 1932; 99: 10503.

  • [17]

    Rambar AC. Mumps: use of convalescent serum in the treatment and prophylaxis of orchitis. Amer J Dis Child 1946; 71: 113.

  • [18]

    Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Amer J Public Health Nations Health 1935; 25: 5958.

  • [19]

    Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH. Hark back: passive immunotherapy for influenza and other serious infections. Crit care med 2010; 38: e66-e73.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [20]

    Luke TC, Kilbane EM, Jackson, JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Inter Med 2006; 145: 599609.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [21]

    Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clinic Infect Dis 2011; 52: 44756.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [22]

    Sahr F, Ansumana R, Massaquoi TA, Idriss B R, Sesay FR, Lamin JM, Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. J Infect 2017; 74: 3029.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [23]

    Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton, KA, Passive immunotherapy: assessment of convalescent serum against Ebola virus Makona infection in nonhuman primates. J Infect Dis 2016; 214(Suppl. 3): S36774.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [24]

    De Greve H, Virdi V, Bakshi S, Depicker A. Simplified monomeric VHH-Fc antibodies provide new opportunities for passive immunization. Curr Opin Biotechnol 2020; 61: 96101.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [25]

    Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000 Res 2020; 9: 72.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • [26]

    World Health Organization. Coronavirus disease (COVID-19). Situation report 104. 3 May 2020.

  • [27]

    Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Treatment with convalescent plasma for COVID‐19 patients in Wuhan, China. J Med Virol 2020.

  • [28]

    China seeks plasma from recovered patients to treat virus|time. Available from: https://time.com/5784286/covid-19-china-plasma-treatment/.

    • Export Citation
  • [29]

    Passive immunisation' can save COVID-19 patients: Pakistan's top hematologist | Tribune. Available at https:/tribune.com.pk›story.

    • Export Citation
  • [30]

    Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368: m1256.

  • [31]

    Haseltine WA. Why Researchers are exploring antibodies from recovered patients for possible treatment and prevention of COVID-19. Forbes Magazine 2020.

    • Search Google Scholar
    • Export Citation
  • [32]

    Sheehy A. Antibodies in the blood of COVID-19 survivors know how to beat coronavirus – and researchers are already testing new treatments that harness them. The Conversation US 2020.

    • Search Google Scholar
    • Export Citation
  • [33]

    European commission directorate-general for health and food safety. An EU programme of COVID-19 convalescent plasma collection and transfusion 2020.

    • Search Google Scholar
    • Export Citation
  • [34]

    Freund A. Coronavirus drugs: Can antibodies from survivors help? Deutsche Welle 2020.

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
May 2020 0 0 0
Jun 2020 0 0 0
Jul 2020 107 61 34
Aug 2020 21 0 0
Sep 2020 164 0 0
Oct 2020 135 0 0
Nov 2020 0 0 0